<DOC>
	<DOC>NCT01508962</DOC>
	<brief_summary>The goal of PRESS-ALS is to study the earliest manifestations of disease in people with early ALS in whom some areas of the body are not yet affected.</brief_summary>
	<brief_title>PRE-Symptomatic Studies in ALS</brief_title>
	<detailed_description />
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Inclusion Criteria ALS group: Subject is a male or female, aged at least 18 years. Subject is affected with ALS (familial or sporadic). Subject has at least one limb in which there is no symptomatic upper and lower motor neuron dysfunction. Subject is willing and able to comply with all study procedures. Subject agrees to provide signed and dated informed consent form. Control group: Subject is a male or female, aged at least 18 years. Subject is not affected with ALS or an ALSrelated disorder. Subject does not have a family history (i.e., at least 2 biological relatives) of ALS or an ALSrelated disorder. Subject is willing and able to comply with all study procedures. Subject agrees to provide signed and dated informed consent form. Exclusion Criterion â€¢ Any condition or situation which, in the PI's opinion, could confound the biomarker data or may interfere significantly with the individual's participation and compliance with the study protocol, including but not limited to neurological, psychological and/or medical conditions (e.g., multiple sclerosis, neuropathy, myelopathy).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Disease onset</keyword>
	<keyword>Disease progression</keyword>
</DOC>